Lifebio Laboratories LLC

Fds Pharma

Fds Pharma Ass.

Alexandr Gabibovich Gabibov

Natalya Alexandrovna Ponomarenko

Alexandr Viktorovich Demin

Aleksey Anatolievich Belogurov

Alexandr Vladimirovich Kolesnikov

Ivan Ivanovich Vorobiev

Elena Sergeevna Alexandrova

Natalia Alexandrovna Ponomarenko

Aleksey Anatolievich Belogurov Jr

Novel oligopeptides, combinations thereof and fusion proteins composed of the above-mentioned oligopeptides are disclosed. Oligopeptides are homologous in amino acid sequence to the selected parts of the amino acid sequence of human myelin basic protein (MBP) and are capable to ameliorate the progression of multiple sclerosis by means of binding to and inactivation of epitope-specific anti MBP catalytic auto antibodies (ESAMBPCAA) involved into binding and catalytic degradation of MBP in course of progression of Multiple Sclerosis.

Composition for treatment of multiple sclerosis

A method for producing catalytic antibodies to proteins and peptides, in particular to gp120, using animals having spontaneous and induced autoimmune pathologies. The method makes it possible to create a catalytic vaccine which can when injected to a patient to exhibits adhesive properties in relation to antigen simultaneously with a destructive function, thereby suspending the progression of disease. The method for the autoimmunisation of animal lines SJL by fused proteins containing classical peptide epitope which develops pathology of an animal by protein fragments gp120 accompanied with an interest target catalytic antibody is disclosed. Also the method for immunising autoimmune animals by highly reactive chemical compositions which can perform a covalent selection of catalytic clones containing peptide fragments of potential resected portions gp120 is disclosed.

Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence

Growing community of inventors

Moscow, Russia

Alexandr Gabibovich Gabibov